IgA-nefropátia: vizsgálatok itt: Chile

1 trial · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

• 3. fázisTaking people
  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  Where

  Temuco

  Életkor

  18 év to 100 év

  People

  540 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT04557462 · EU 2023-508690-92-00